Hope for Epilepsy Patients, But Treatment Gap Exists Worldwide
An exciting discovery may change the way epilepsy is treated, but if current evidence is any indication, getting the treatment to patients will be a challenge.
feature2
Potential Hepatitis C Breakthrough for Santaris
In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.
FDA Approves Treatment for Rare Swelling Disease
Biopharmaceutical company Dyax Corporation has received regulatory approval to market its drug ecallantide (Kalbitor) for a rare genetic disorder called hereditary angioedema (HAE).
Provectus Reports Positive Preliminary Data for Dermatology Drug
Patients with psoriasis demonstrated 79% improvement in the Psoriasis Scoring Index after four weeks of daily treatment with PH-10.
Clavis and Clovis Sign Licensing Deal for Cancer Drug
Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
Cancer Vaccines: Investing Opportunities Beyond Dendreon
Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
ImmunoGen Signs 2nd Licensing Deal with Amgen
ImmunoGen has licensed its anti-cancer technology to Amgen for an upfront payment of $1 million.
Controversy Over New Breast Cancer Screening Guidelines
The U.S. Preventive Services Task Force recommended this week that women should begin getting routine mammograms at the age of 50 instead of the previously recommended age of 40.
Spherix Shares Rise on Promising Diabetes Drug Data
Shares in Spherix shot up by 77 percent after the biotechnology company announced preliminary Phase III results for its Type 2 diabetes drug candidate.
Adeona’s Experimental RA Drug Does Well in Phase II Trial
Adeona Pharmaceuticals, a developer of medications for CNS and autoimmune diseases, announced data from a Phase II clinical trial of its rheumatoid arthritis drug candidate.